Concepedia

Shi Chang

SC

7

Publications

1.1K

Citations

7

H-Index

1988

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at San Antonio

Dana-Farber Cancer Institute

Dana-Farber Brigham Cancer Center

Northwestern University

Shi Chang is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1988–2012

7

Publications

7

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

George N. Thalmann, Ploutarchos Anezinis, Shi Chang et al. · PubMed · 1994 · 739 citations

, , +14

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

E. Q. Lee, John G. Kuhn, Kathleen R. Lamborn et al. · Neuro-Oncology · 2012 · 110 citations · Full text

, , +17

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Victor A. Levin, Joon H. Uhm, Kurt A. Jaeckle et al. · PubMed · 2000 · 89 citations

, , +19

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas

Jeffrey J. Raizer, L. E. Abrey, Andrew B. Lassman et al. · Neuro-Oncology · 2009 · 53 citations · Full text

Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02)

H. I. Robins, Patrick Y. Wen, Shi Chang et al. · Journal of Clinical Oncology · 2007 · 42 citations

, , +16

Rows per page

1–5 of 7